This screen looks for one thing: a share price that has fallen over three months while both the analyst consensus and our own score stayed positive. It is a disagreement, not a verdict. Either the market has seen something the published views have not caught up with, or the views are right and the price overshot. The screen cannot tell you which — it tells you where to look, and shows the numbers that make each case.
Data as of 2026-11-09. 109 of 470 tracked IPOs qualify. Sorted by the three-month change, biggest fall first. The companion screen, where the price rose while the rating stayed cautious, runs the same test in the other direction.
Price fell, rating held
| what we compute | what you can get elsewhere too | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company | Our balance | Fundamentals | Flags | IPO | Market cap | Last | 3-month | Since IPO | Analyst index | Consensus | Target |
| WYFI | WhiteFiber, Inc. | Leans up +2 medium | loss-making -132.2% revenue +66.2% heavily indebted | Fell on sound metrics, Large daily move, Halved from offer | 2025-08-07 | $427M | $7.65 | -68.9% | -42.2% | 8.2 | Strong Buy (11) | $31.45 +311% |
| UMAC | Unusual Machines, Inc. | Leans up +2 medium | loss-making -75.9% revenue +101.2% | — | 2024-02-14 | $586M | $10.15 | -62.6% | +238.2% | 8.3 | Strong Buy (9) | $30.11 +197% |
| BLZE | Backblaze, Inc. | Leans up +2 weak | loss-making -11.5% revenue +14.3% heavily indebted | Fell, analysts held, Improving confidence, Large daily move, Halved from offer | 2021-11-11 | $489M | $7.27 | -60.1% | -56.7% | 7.1 | Buy (7) | $21.50 +196% |
| BCAX | Bicara Therapeutics Inc. | Leans up +2 weak | — | Fell, analysts held, Monthly spike, Halved from offer | 2024-09-13 | $665M | $9.12 | -59.8% | -49.0% | 7.5 | Buy (14) | $32.17 +253% |
| IREN | IREN Limited | Up +4 strong | loss-making -194.4% revenue +41.1% heavily indebted | Fell on sound metrics, Improving confidence, Monthly spike | 2021-11-17 | $7.7B | $14.41 | -59.5% | -34.0% | 7.0 | Buy (20) | $56.69 +293% |
| ITG | ITG, Inc. | Up +4 strong | profitable 1.1% revenue +15.7% heavily indebted | Fell on sound metrics, Profitable but deeply down, Large daily move, Weekly spike, Halved from offer | 2026-07-01 | $705M | $6.18 | -54.2% | -52.6% | 9.4 | Strong Buy (9) | $11.33 +83% |
| CRDO | Credo Technology Group Holding Ltd | Leans up +3 medium | profitable 33.8% revenue +205.7% | — | 2022-01-27 | $24.7B | $117.76 | -53.5% | +2.1% | 8.3 | Strong Buy (20) | $277.47 +136% |
| EROC | ERock, Inc. | Up +4 strong | loss-making -50.2% revenue +42.5% heavily indebted | Fell on sound metrics, Halved from offer | 2026-06-10 | $2.3B | $7.25 | -51.7% | -56.6% | 7.5 | Buy (8) | $18.88 +160% |
| CADL | Candel Therapeutics, Inc. | Leans up +2 weak | heavily indebted | Fell, analysts held, Improving confidence, Large daily move, Weekly spike | 2021-07-27 | $486M | $5.13 | -49.0% | -28.1% | 10.0 | Strong Buy (10) | $17.67 +244% |
| INIO | Innio N.V. | Leans up +3 medium | profitable 2.7% revenue +22.1% heavily indebted | Lock-up expiry, Fell on sound metrics, Halved from offer | 2026-06-04 | $10.9B | $12.81 | -48.2% | -35.7% | 6.0 | Buy (10) | $31.40 +145% |
| APMD | Apnimed, Inc. | Leans up +2 weak | profitable 83.8% revenue +380.1% | — | 2026-07-31 | $704M | $17.25 | -48.0% | +7.8% | 10.0 | Strong Buy (4) | $50.33 +192% |
| QNT | Quantinuum Inc. | Leans up +3 medium | loss-making -106.4% revenue +34.6% heavily indebted | Lock-up expiry, Fell on sound metrics | 2026-06-04 | $9.4B | $27.96 | -46.4% | -51.4% | 8.9 | Strong Buy (14) | $71.15 +154% |
| RAPP | Rapport Therapeutics, Inc. | Leans up +2 weak | pre-revenue heavily indebted | — | 2024-06-07 | $1.6B | $23.59 | -46.0% | +58.2% | 9.7 | Strong Buy (16) | $64.21 +172% |
| NNE | NANO Nuclear Energy Inc. | Leans up +3 weak | pre-revenue | — | 2024-05-08 | $597M | $9.97 | -43.3% | +174.0% | 7.2 | Buy (9) | $34.75 +249% |
| CLYM | Climb Bio, Inc. | Leans up +3 weak | — | — | 2021-08-10 | $609M | $9.28 | -40.6% | -21.6% | 9.4 | Strong Buy (16) | $28.40 +206% |
| AUR | Aurora Innovation, Inc. | Leans up +2 medium | pre-revenue revenue +200.0% heavily indebted | Halved from offer | 2021-05-06 | $8.5B | $3.84 | -39.6% | — | 5.4 | Buy (13) | $11.55 +201% |
| GLUE | Monte Rosa Therapeutics, Inc. | Up +4 strong | loss-making -186.2% revenue +63.5% heavily indebted | Fell on sound metrics, Halved from offer | 2021-06-24 | $801M | $8.91 | -39.1% | -50.4% | 9.0 | Strong Buy (10) | $25.38 +185% |
| AVEX | AEVEX Corp. | Leans up +2 weak | loss-making -2.8% revenue +10.4% | Lock-up expiry, Fell, analysts held, Large daily move, Weekly spike | 2026-04-17 | $1.6B | $12.86 | -38.1% | -29.3% | 7.5 | Buy (10) | $25.44 +98% |
| GHRS | GH Research PLC | Leans up +3 weak | — | — | 2021-06-25 | $1.3B | $18.56 | -36.3% | +31.5% | 8.5 | Strong Buy (10) | $42.89 +131% |
| MPLT | MapLight Therapeutics, Inc. | Leans up +3 medium | — | Halved from offer | 2025-10-27 | $403M | $6.42 | -35.5% | -58.3% | 7.7 | Strong Buy (15) | $26.54 +313% |
| KRMN | Karman Holdings Inc. | Up +4 strong | profitable 7.5% revenue +36.6% heavily indebted | Improving confidence | 2025-02-13 | $5.4B | $32.99 | -34.2% | +58.6% | 8.6 | Strong Buy (14) | $67.00 +103% |
| ATTO | Attovia Therapeutics, Inc. | Leans up +2 weak | pre-revenue revenue -100.0% | Shrinking revenue | 2026-08-05 | $691M | $15.58 | -33.4% | -12.3% | 8.0 | Strong Buy (5) | $43.20 +177% |
| AKTS | Aktis Oncology, Inc. | Up +4 strong | pre-revenue revenue +336.9% heavily indebted | — | 2026-01-09 | $927M | $16.40 | -32.8% | -14.8% | 9.5 | Strong Buy (10) | $35.88 +119% |
| KARD | Kardigan, Inc. | Leans up +3 weak | heavily indebted | — | 2026-06-18 | $1.3B | $12.52 | -32.8% | -20.9% | 9.4 | Strong Buy (9) | $41.00 +227% |
| KGS | Kodiak Gas Services, Inc. | Leans up +2 medium | profitable 11.3% revenue +12.8% heavily indebted | — | 2023-06-29 | $4.5B | $42.69 | -32.4% | +198.0% | 8.3 | Strong Buy (15) | $72.64 +70% |
| WRD | WeRide Inc. | Leans up +2 medium | loss-making -199.0% revenue +89.6% heavily indebted | Halved from offer | 2024-10-25 | $1.4B | $3.27 | -31.9% | -74.4% | 7.7 | Strong Buy (13) | $12.30 +277% |
| IMMX | Immix Biopharma, Inc. | Leans up +3 weak | — | — | 2021-12-16 | $657M | $7.04 | -30.9% | +41.2% | 7.9 | Strong Buy (7) | $23.80 +238% |
| ALAB | Astera Labs, Inc. | Up +4 medium | profitable 29.6% revenue +115.1% | — | 2024-03-20 | $38.8B | $211.60 | -30.7% | +642.1% | 6.0 | Buy (25) | $344.15 +63% |
| DSGN | Design Therapeutics, Inc. | Leans up +3 weak | — | Halved from offer | 2021-03-26 | $670M | $9.32 | -30.7% | — | 8.8 | Strong Buy (8) | $21.57 +131% |
| AIP | Arteris, Inc. | Leans up +3 weak | loss-making -44.8% revenue +22.3% heavily indebted | Improving confidence | 2021-10-27 | $962M | $18.91 | -30.5% | +38.5% | 10.0 | Strong Buy (7) | $33.00 +75% |
| AMBQ | Ambiq Micro, Inc. | Up +4 weak | loss-making -29.7% revenue -4.7% | Improving confidence, Weekly spike | 2025-07-30 | $1.2B | $45.60 | -30.1% | +122.1% | 6.4 | Buy (7) | $66.71 +46% |
| ARM | Arm Holdings plc | Leans up +2 medium | profitable 17.1% revenue +22.8% heavily indebted | — | 2023-09-14 | $203.9B | $177.17 | -29.8% | +321.0% | 5.4 | Buy (43) | $272.43 +54% |
| FIGR | Figure Technology Solutions, Inc. | Up +6 strong | profitable 33.7% revenue +55.7% heavily indebted | Improving confidence | 2025-09-11 | $5.7B | $25.84 | -29.5% | -3.3% | 6.5 | Buy (10) | $47.20 +83% |
| BRVE | Braveheart Bio, Inc. | Leans up +3 weak | — | — | 2026-08-06 | $1.6B | $19.27 | -29.1% | +23.3% | 10.0 | Strong Buy (5) | $45.50 +136% |
| SIND | Sinda Ltd. | Leans up +3 weak | — | — | 2026-06-26 | $1.9B | $11.18 | -29.1% | -8.2% | 7.5 | Buy (6) | $18.40 +65% |
| MNR | Mach Natural Resources LP | Leans up +3 medium | profitable 20.7% revenue +21.2% liquidity 0.8 | Fell on sound metrics, Profitable but deeply down, Thin liquidity, Halved from offer | 2023-10-25 | $1.5B | $8.09 | -28.8% | -45.3% | 7.8 | Strong Buy (9) | $16.29 +101% |
| BROS | Dutch Bros Inc. | Leans up +2 medium | profitable 5.1% revenue +27.9% heavily indebted | — | 2021-09-15 | $6.4B | $34.15 | -28.8% | +102.8% | 8.5 | Strong Buy (27) | $55.04 +61% |
| KLRA | Kailera Therapeutics, Inc. | Leans up +2 weak | — | Lock-up expiry | 2026-04-17 | $1.7B | $11.58 | -28.3% | -22.3% | 9.3 | Strong Buy (7) | $43.00 +271% |
| PICS | PicS N.V. | Up +5 strong | profitable 15.7% revenue +65.0% heavily indebted | Fell on sound metrics, Profitable but deeply down, Monthly spike, Halved from offer | 2026-01-29 | $962M | $4.85 | -27.4% | -61.3% | 8.9 | Strong Buy (9) | $16.76 +246% |
| BKV | BKV Corporation | Leans up +3 medium | profitable 16.2% revenue +41.6% heavily indebted | — | 2024-09-26 | $2.1B | $17.88 | -26.9% | +22.4% | 9.6 | Strong Buy (11) | $31.27 +75% |
| STUB | StubHub Holdings, Inc. | Up +4 strong | loss-making -91.3% revenue -1.4% heavily indebted | Fell, analysts held, Improving confidence, Halved from offer | 2025-09-17 | $2.0B | $4.84 | -25.4% | -77.8% | 5.4 | Buy (14) | $9.21 +90% |
| TYRA | Tyra Biosciences, Inc. | Leans up +2 weak | — | — | 2021-09-15 | $1.4B | $19.73 | -23.6% | +26.2% | 8.7 | Strong Buy (15) | $47.45 +140% |
| SKHY | SK hynix Inc. | Up +5 strong | profitable 85.6% revenue +46.8% heavily indebted | Improving confidence | 2026-07-10 | $663.0B | $119.20 | -23.1% | +2.6% | 7.7 | Strong Buy (15) | $259.50 +118% |
| GENB | Generate Biomedicines, Inc. | Up +4 strong | pre-revenue revenue +55.9% heavily indebted | — | 2026-02-27 | $1.6B | $10.37 | -23.1% | -23.7% | 8.0 | Strong Buy (5) | $26.25 +153% |
| GFS | GLOBALFOUNDRIES Inc. | Leans up +3 weak | profitable 2.8% revenue +0.6% heavily indebted | Improving confidence | 2021-10-28 | $23.1B | $38.94 | -22.4% | -4.5% | 4.8 | Buy (23) | $64.77 +66% |
| FIG | Figma, Inc. | Up +4 strong | loss-making -40.2% revenue +41.0% heavily indebted | Fell on sound metrics | 2025-07-31 | $10.4B | $16.26 | -22.2% | -30.4% | 2.8 | Buy (16) | $27.41 +69% |
| HAWK | HawkEye 360, Inc. | Up +4 strong | loss-making -16.2% revenue +162.6% heavily indebted | Lock-up expiry, Fell on sound metrics, Improving confidence, Large daily move, Weekly spike, Monthly spike | 2026-05-07 | $1.8B | $18.08 | -21.6% | -35.5% | 8.6 | Strong Buy (11) | $27.70 +53% |
| STDN | Standard Nuclear, Inc. | Leans up +2 weak | pre-revenue | Fell, analysts held | 2026-07-16 | $1.7B | $9.01 | -20.7% | -31.5% | 8.3 | Strong Buy (9) | $16.88 +87% |
| ANL | Adlai Nortye Group Ltd. | Leans up +2 weak | heavily indebted | Fell, analysts held | 2023-09-29 | $683M | $9.06 | -20.5% | -58.0% | 10.0 | Strong Buy (7) | $29.50 +226% |
| ETOR | eToro Group Ltd. | Up +4 strong | profitable 2.4% revenue +9.4% heavily indebted | Fell on sound metrics, Profitable but deeply down, Halved from offer | 2025-05-14 | $1.8B | $19.50 | -20.0% | -57.5% | 6.0 | Buy (15) | $36.60 +88% |
| MAIR | Madison Air Solutions Corporation | Leans up +3 medium | profitable 6.7% revenue +34.1% heavily indebted | Lock-up expiry, Improving confidence | 2026-04-16 | $14.1B | $23.19 | -19.6% | -11.1% | 8.5 | Strong Buy (10) | $34.00 +47% |
| HOOD | Robinhood Markets, Inc. | Leans up +3 medium | profitable 39.0% revenue +51.6% heavily indebted | Improving confidence | 2021-07-29 | $70.1B | $68.65 | -19.1% | +112.3% | 6.4 | Buy (32) | $127.77 +86% |
| SSMR | Sunshine Silver Mining & Refining Company | Leans up +3 medium | pre-revenue revenue +421.8% | Lock-up expiry | 2026-06-04 | $1.9B | $12.04 | -18.8% | -19.7% | 6.7 | Buy (6) | $19.08 +58% |
| RIVN | Rivian Automotive, Inc. | Up +5 weak | loss-making -45.9% revenue +8.4% heavily indebted | Fell, analysts held, Upgrade, Improving confidence, Halved from offer | 2021-11-10 | $17.8B | $11.29 | -18.1% | -84.9% | 3.2 | Buy (25) | $17.94 +59% |
| MBX | MBX Biosciences, Inc. | Up +4 weak | — | Improving confidence | 2024-09-13 | $2.8B | $53.41 | -18.0% | +270.4% | 8.8 | Strong Buy (12) | $95.09 +78% |
| CAVA | CAVA Group, Inc. | Leans up +2 weak | profitable 4.5% revenue +22.4% heavily indebted | Improving confidence | 2023-06-15 | $6.8B | $51.23 | -18.0% | +177.7% | 6.1 | Buy (27) | $75.42 +47% |
| CRCL | Circle Internet Group, Inc. | Leans up +3 medium | profitable 15.3% revenue +63.9% | — | 2025-06-05 | $16.0B | $51.88 | -16.6% | +113.1% | 4.1 | Buy (29) | $102.37 +97% |
| RLX | RLX Technology Inc. | Up +4 medium | profitable 21.9% revenue +48.0% | Halved from offer | 2021-01-22 | $1.9B | $1.46 | -16.6% | — | 8.3 | Strong Buy (6) | $2.78 +90% |
| Q | Qnity Electronics, Inc. | Leans up +2 medium | profitable 10.2% revenue +9.7% heavily indebted | — | 2025-10-27 | $24.7B | $113.63 | -15.9% | — | 8.5 | Strong Buy (10) | $173.30 +53% |
| VOR | Vor Biopharma Inc. | Leans up +3 weak | — | Halved from offer | 2021-02-05 | $1.2B | $18.52 | -15.6% | — | 8.5 | Strong Buy (10) | $39.00 +111% |
| IPSC | Century Therapeutics, Inc. | Leans up +3 medium | revenue +1556.8% heavily indebted | Halved from offer | 2021-06-17 | $300M | $1.32 | -15.4% | — | 7.0 | Buy (5) | $4.75 +260% |
| AUNA | Auna S.A. | Up +4 strong | profitable 0.3% revenue -0.0% heavily indebted | Fell on sound metrics, Profitable but deeply down, Halved from offer | 2024-03-22 | $340M | $3.90 | -14.7% | -63.2% | 6.4 | Buy (7) | $6.99 +79% |
| BLSM | BlossomHill Therapeutics, Inc. | Leans up +3 weak | — | — | 2026-08-07 | $446M | $14.41 | -14.4% | -19.4% | 9.0 | Strong Buy (5) | $35.40 +146% |
| RELY | Remitly Global, Inc. | Up +5 strong | profitable 19.1% revenue +29.4% heavily indebted | Fell on sound metrics, Profitable but deeply down, Halved from offer | 2021-09-23 | $4.8B | $20.06 | -14.3% | -40.5% | 9.0 | Strong Buy (10) | $32.00 +60% |
| WBI | WaterBridge Infrastructure LLC | Leans up +3 medium | profitable 1.2% revenue +66.2% heavily indebted | Improving confidence | 2025-09-17 | $3.4B | $24.99 | -13.6% | +55.5% | 5.6 | Buy (8) | $36.75 +47% |
| TCBX | Third Coast Bancshares, Inc. | Leans up +3 medium | profitable 30.7% revenue +21.9% heavily indebted | Improving confidence | 2021-11-09 | $661M | $37.60 | -13.3% | +66.4% | 4.3 | Buy (7) | $47.36 +26% |
| CINT | CI&T Inc. | Leans up +2 medium | profitable 6.8% revenue +11.6% heavily indebted | Profitable but deeply down, Halved from offer | 2021-11-10 | $390M | $2.87 | -13.3% | -79.5% | 6.5 | Buy (10) | $5.63 +96% |
| DC | Dakota Gold Corp. | Leans up +3 weak | — | — | 2022-04-05 | $715M | $4.36 | -13.1% | — | 9.2 | Strong Buy (6) | $12.26 +181% |
| AFRM | Affirm Holdings, Inc. | Leans up +3 medium | profitable 43.9% revenue +32.1% heavily indebted | — | 2021-01-13 | $22.1B | $56.91 | -12.6% | — | 7.2 | Buy (36) | $95.81 +68% |
| JCAP | Jefferson Capital, Inc. | Leans up +2 medium | profitable 23.5% revenue +41.5% heavily indebted | Large daily move | 2025-06-26 | $1.2B | $20.94 | -11.7% | +42.4% | 7.0 | Buy (5) | $28.60 +37% |
| VIK | Viking Holdings Ltd | Leans up +3 medium | profitable 19.3% revenue +21.9% liquidity 0.8 heavily indebted | Thin liquidity, Upgrade, Improving confidence | 2024-05-01 | $40.1B | $95.00 | -10.0% | +272.6% | 8.9 | Strong Buy (23) | $110.05 +16% |
| INBX | Inhibrx Biosciences, Inc. | Leans up +3 weak | revenue +550.0% | Improving confidence | 2024-05-28 | $1.2B | $74.33 | -9.5% | — | 7.5 | Buy (4) | $266.67 +259% |
| AVAH | Aveanna Healthcare Holdings Inc. | Leans up +3 medium | profitable 11.4% revenue +20.2% heavily indebted | Improving confidence | 2021-04-29 | $2.5B | $10.70 | -9.4% | — | 6.4 | Buy (11) | $15.20 +42% |
| KSPI | Joint Stock Company Kaspi.kz | Leans up +2 medium | profitable 24.3% revenue +59.8% heavily indebted | — | 2024-01-19 | $17.1B | $85.80 | -9.2% | -0.5% | 5.7 | Buy (7) | $106.52 +24% |
| ZBIO | Zenas BioPharma, Inc. | Leans up +3 medium | pre-revenue revenue +100.0% | — | 2024-09-13 | $1.9B | $25.04 | -8.2% | +61.0% | 8.8 | Strong Buy (8) | $47.88 +91% |
| AS | Amer Sports, Inc. | Leans up +2 medium | profitable 7.3% revenue +26.7% heavily indebted | — | 2024-02-01 | $17.4B | $29.51 | -8.1% | +124.5% | 8.5 | Strong Buy (27) | $47.47 +61% |
| LB | LandBridge Corporation | Leans up +2 medium | profitable 17.1% revenue +81.1% heavily indebted | — | 2024-06-28 | $5.6B | $71.43 | -8.0% | +424.8% | 4.3 | Buy (7) | $89.57 +25% |
| AURA | Aura Biosciences, Inc. | Leans up +2 weak | heavily indebted | Fell, analysts held | 2021-10-29 | $740M | $6.98 | -7.4% | -53.3% | 9.2 | Strong Buy (6) | $16.60 +138% |
| FLY | Firefly Aerospace Inc. | Leans up +3 medium | loss-making -88.4% revenue +162.9% heavily indebted | Fell on sound metrics, Weekly spike, Monthly spike, Halved from offer | 2025-08-07 | $4.3B | $19.52 | -7.2% | -56.0% | 5.9 | Buy (11) | $36.64 +88% |
| TPG | TPG Inc. | Leans up +2 medium | profitable 7.5% revenue +27.0% heavily indebted | — | 2022-01-13 | $18.6B | $45.59 | -6.8% | +69.5% | 5.9 | Buy (17) | $59.53 +31% |
| VINP | Vinci Compass Investments Ltd. | Leans up +3 medium | profitable 25.7% revenue +62.7% heavily indebted | Halved from offer | 2021-01-28 | $577M | $8.22 | -6.7% | — | 7.5 | Buy (6) | $12.63 +54% |
| BBNX | Beta Bionics, Inc. | Leans up +3 medium | loss-making -65.3% revenue +53.9% | — | 2025-01-30 | $893M | $13.32 | -6.5% | -2.2% | 6.7 | Buy (15) | $25.10 +88% |
| PHVS | Pharvaris N.V. | Leans up +3 weak | — | — | 2021-02-05 | $2.3B | $31.66 | -5.5% | — | 8.9 | Strong Buy (14) | $58.16 +84% |
| FSBC | Five Star Bancorp | Leans up +2 medium | profitable 41.3% revenue +25.7% heavily indebted | — | 2021-05-05 | $1.1B | $41.87 | -5.4% | — | 5.0 | Buy (5) | $51.40 +23% |
| LIFE | Ethos Technologies Inc. | Leans up +2 medium | loss-making -16.2% revenue +52.0% | — | 2026-01-29 | $2.2B | $32.13 | -5.4% | +122.7% | 7.8 | Strong Buy (9) | $53.38 +66% |
| SPCX | Space Exploration Technologies Corp. | Up +4 strong | loss-making -8.6% revenue +33.2% heavily indebted | Improving confidence | 2026-06-12 | $1.89T | $138.43 | -4.9% | +4.7% | 6.5 | Buy (40) | $255.63 +85% |
| VG | Venture Global, Inc. | Leans up +3 medium | profitable 31.1% revenue +176.9% liquidity 0.9 heavily indebted | Profitable but deeply down, Thin liquidity, Improving confidence | 2025-01-24 | $33.1B | $12.13 | -4.4% | -41.3% | 5.0 | Buy (17) | $17.56 +45% |
| PAYP | PayPay Corporation | Up +5 strong | profitable 16.3% revenue +25.9% heavily indebted | — | 2026-03-12 | $9.7B | $12.91 | -4.1% | -13.1% | 7.7 | Strong Buy (13) | $23.67 +83% |
| NXT | Nextpower Inc. | Up +4 medium | profitable 16.0% revenue +20.3% | Improving confidence | 2023-02-09 | $14.3B | $75.95 | -4.1% | +244.0% | 7.7 | Strong Buy (30) | $127.90 +68% |
| SGMT | Sagimet Biosciences Inc. | Leans up +2 weak | — | — | 2023-07-14 | $729M | $9.62 | -2.0% | -37.2% | 7.5 | Buy (12) | $27.27 +183% |
| FRBT | Forbright, Inc. | Leans up +3 medium | profitable 13.7% revenue +30.2% heavily indebted | — | 2026-06-11 | $951M | $17.11 | -1.9% | +2.5% | 6.7 | Buy (6) | $23.25 +36% |
| YMM | Full Truck Alliance Co. Ltd. | Up +6 strong | profitable 33.0% revenue +11.1% | Fell on sound metrics, Profitable but deeply down, Halved from offer | 2021-06-22 | $9.0B | $9.06 | -1.7% | -56.5% | 7.3 | Buy (15) | $12.51 +38% |
| DLO | DLocal Limited | Up +5 medium | profitable 15.0% revenue +46.6% | Improving confidence, Halved from offer | 2021-06-03 | $3.9B | $12.67 | -1.6% | — | 7.5 | Buy (10) | $18.50 +46% |
| PTRN | Pattern Group Inc. | Leans up +3 medium | profitable 3.6% revenue +39.3% heavily indebted | Upgrade | 2025-09-19 | $3.6B | $18.86 | -1.4% | +32.4% | 8.9 | Strong Buy (9) | $27.88 +48% |
Showing 94 of 470 tracked IPOs. Our balance, the flags, the fundamentals and the analyst figures come from the weekly run of 2026-11-16. Prices are refreshed daily and were last taken on 2026-11-19; a thinly traded company shows its most recent trade, which may be older. Use the filters to narrow the list, or click a column heading to sort.
The three-month window is deliberate. A week is noise and a year buries the move in the IPO itself; three months is long enough for a repricing and short enough that the published views have had time to react and have not. Where a company carries a Lock-up expiry flag, part of the fall may be supply rather than sentiment — the dates are on the Key Dates page, with how many normal trading sessions the unlocking stock would take to absorb.
How to read this. Our score runs from −10 to +10 and is computed here from the filings and the price history, not copied from anyone — the Scores page sets out what goes into it and Method says where every figure comes from. Our view is the direction that score leans, in words. Consensus is the analyst consensus with the number of analysts behind it in brackets; a consensus resting on four or five people is not the same object as one resting on thirty, which is why the count is always shown. Implied upside is the consensus target against the latest close. The 3-month change is highlighted where the move is 40% or more in either direction. Of the 470 listed IPOs we track, 105 are left out of both screens before anything is ranked: 9 are under a takeover offer, 32 carry no consensus target at all, 36 are followed by fewer than four analysts, 7 trade below a dollar, and 21 show an implied upside above 300%, counting each by the first test it fails. Two of those deserve a word. A target three times the share price is almost always a target nobody has revised, not a bullish call. And a company under a takeover offer is not a disagreement at all: the price tracks the bid and the rating goes to hold, which is the mechanism working, not a gap between the market and the page. A disagreement is not a forecast and not a recommendation: it says the price and the published view have moved apart, and gives you the pieces to work out which one you find more convincing. Nothing on this page is a recommendation to buy or sell.
